Literature DB >> 21963956

Antimicrobial antibodies are associated with a Crohn's disease-like phenotype after ileal pouch-anal anastomosis.

Andrea D Tyler1, Raquel Milgrom, Wei Xu, Joanne M Stempak, A Hillary Steinhart, Robin S McLeod, Gordon R Greenberg, Zane Cohen, Mark S Silverberg.   

Abstract

BACKGROUND & AIMS: Pouchitis and Crohn's disease (CD)-like (CDL) complications of the pouch occur at rates near 50% and 20%, respectively, after colectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We investigated whether antimicrobial antibodies are associated with pouch outcome after IPAA.
METHODS: We studied clinical and endoscopic data from 399 individuals with UC who underwent colectomy with IPAA at Mount Sinai Hospital in Toronto, Canada; patients were classified as no pouchitis (NP), chronic pouchitis (CP), or CDL. Serum samples were analyzed from 341 patients for antibodies against Saccharomyces cerevisiae (ASCA), OmpC, CBir1, and perinuclear antineutrophil cytoplasmic antibody (pANCA).
RESULTS: Of the subjects, 70.7% had NP, 16.8% developed CP, and 12.5% developed CDL. Smoking was associated with CDL (P = .003). Ashkenazi Jewish individuals more commonly had CP (P = .008). Of patients with CDL, 53.5% and 14.0% had positive test results for anti-CBir1 and ASCA (immunoglobulin G), respectively, compared with 21.4% and 3.8% of those with NP and 28.3% and 5.0% of those with CP (P < .0001 and P = .03). Anti-CBir1 was associated with CDL, compared with NP (P = 2.8 × 10(-5); odds ratio [OR], 4.2; 95% confidence interval [CI], 2.2-8.3) or CP (P = .011; OR, 2.9; 95% CI, 1.3-6.6). ASCA immunoglobulin G was associated with CDL, compared with patients with NP (P = .01; OR, 4.1; 95% CI, 1.4-12.3). In a combined model, pANCA and the antimicrobial antibodies were associated with CP (P = .029) and CDL (P = 4.7 × 10(-4)).
CONCLUSIONS: Antimicrobial antibodies and pANCA are associated with inflammatory complications of the pouch. The CDL phenotype is associated with factors that characterize Crohn's disease, including smoking, anti-CBir1, and ASCA.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963956     DOI: 10.1016/j.cgh.2011.09.016

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  17 in total

Review 1.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

2.  Infliximab to Treat Refractory Inflammation After Pelvic Pouch Surgery for Ulcerative Colitis.

Authors:  Orlaith B Kelly; Morgan Rosenberg; Andrea D Tyler; Joanne M Stempak; A Hillary Steinhart; Zane Cohen; Gordon R Greenberg; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

3.  The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis.

Authors:  Edward L Barnes; Bharati Kochar; Hilary R Jessup; Hans H Herfarth
Journal:  Inflamm Bowel Dis       Date:  2019-08-20       Impact factor: 5.325

Review 4.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

5.  Microbiome Heterogeneity Characterizing Intestinal Tissue and Inflammatory Bowel Disease Phenotype.

Authors:  Andrea D Tyler; Richard Kirsch; Raquel Milgrom; Joanne M Stempak; Boyko Kabakchiev; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

6.  Serological, genetic and clinical associations with increased health-care resource utilization in inflammatory bowel disease.

Authors:  Phillip Gu; Anshika Kapur; Dalin Li; Talin Haritunians; Eric Vasiliauskas; David Q Shih; Stephan R Targan; Brennan Mr Spiegel; Dermot Pb Mcgovern; Jeanne T Black; Gil Y Melmed
Journal:  J Dig Dis       Date:  2018-01       Impact factor: 2.325

Review 7.  Review article: the pathogenesis of pouchitis.

Authors:  K M Schieffer; E D Williams; G S Yochum; W A Koltun
Journal:  Aliment Pharmacol Ther       Date:  2016-08-24       Impact factor: 8.171

8.  Serologic markers associated with development of Crohn's disease after ileal pouch anal anastomosis for ulcerative colitis.

Authors:  Brindusa Truta; Dan X Li; Uma Mahadevan; Elena R Fisher; Yunn-Y Chen; Kim Grace; Fernando Velayos; Jonathan P Terdiman
Journal:  Dig Dis Sci       Date:  2013-10-04       Impact factor: 3.199

Review 9.  Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases.

Authors:  Marla Dubinsky; Jonathan Braun
Journal:  Gastroenterology       Date:  2015-08-15       Impact factor: 22.682

10.  Does a missed obstetric anal sphincter injury at time of delivery affect short-term functional outcome?

Authors:  L Ramage; C Yen; S Qiu; C Simillis; C Kontovounisios; E Tan; P Tekkis
Journal:  Ann R Coll Surg Engl       Date:  2017-09-15       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.